Compensatory upregulation of parallel signaling through the MEK/ERK1/2 pathway in response to PI3K/Akt inhibition, is an emerging theme in cancer cell signal transduction, because it potentially mediates resistance to drug-induced growth inhibition [37]. Here, AKT1 is linked to cancer.